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Abstract
Background: One of the major complications of Plasmodium falciparum infection is cerebral malaria (CM), which
causes one million deaths worldwide each year, results in long-term neurological sequelae and the treatment for
which is only partially effective. Statins are recognized to have an immunomodulatory action, attenuate sepsis and
have a neuroprotective effect. Atorvastatin (AVA) has shown in vitro anti-malarial activity and has improved the
activity of mefloquine (MQ) and quinine.
Methods: The efficiency of 40 mg/kg intraperitoneal AVA, alone or in association with MQ, was assessed in an
experimental Plasmodium berghei ANKA rodent parasite model of CM and performed according to different
therapeutic schemes. The effects on experimental CM were assessed through the evaluation of brain
histopathological changes and neuronal apoptosis by TUNEL staining.
Results: AVA alone in the therapeutic scheme show no effect on survival, but the prophylactic scheme employing AVA
associated with MQ, rather than MQ alone, led to a significant delay in mouse death and had an effect on the onset of
CM symptoms and on the level of parasitaemia. Histopathological findings show a correlation between brain lesions
and CM onset. A neuronal anti-apoptotic effect of AVA in the AVA + MQ combination was not shown.
Conclusions: The combination of AVA and MQ therapy led to a significant delay in mouse mortality. There were
differences in the incidence, time to cerebral malaria and the level of parasitaemia when the drug combination
was administered to mice. When used in combination with MQ, AVA had a relevant effect on the in vivo growth
inhibition and clinical outcome of P. berghei ANKA-infected mice.
Background
The two major complications of Plasmodium falciparum
infections are cerebral malaria (CM) and severe anae-
mia, with an estimated one million deaths worldwide
each year, especially in children under five years old in
sub-Saharan Africa [1]. Neurological sequelae range
from 3-10% in adults, and 25% of child survivors present
long-term cognitive impairments [2,3]. CM pathogenesis
is multi-factorial and still not fully understood. Post-
mortem examination of the brain reveals adherence and
sequestration of parasitized red blood cells (pRBC), leu-
cocytes and platelets, followed by plugging of microves-
sels, necrosis, haemorrhages and oedema [4]. The major
hypothesis is that infection triggers the overproduction
of pro-inflammatory Th1 cytokines, such as tumour
necrosis factor (TNF), interferon-g (IFN-g), lymphotoxin
(LT) and interleukin-12 (IL-12), leading to the up-regu-
lation of leucocyte adhesion molecules (intercellular
adhesion molecule-1 ICAM-1, vascular cell adhesion
molecule-1 VCAM-1) on the cerebral microvascular
endothelium, sequestration of pRBC, endothelial altera-
tions and vascular obstruction. Additionally, cytokines
might modify biochemical cerebral pathways [4-6]. CD8
+ and NK/T lymphocyte cytotoxicity and cell trafficking
should be also key players in CM pathogenesis [7-9].
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Malarial deaths occur, despite effective anti-malarial
compounds such as quinine or artemisinin-derivatives
combinations. Therefore, a number of adjunct therapies
have been proposed, including corticosteroids, osmotic
agents, desferrioxamine, exchange transfusion, N-acetyl
cysteine, pentoxifylline, hyper immune serum, anti-TNF
antibodies, agents for the enhancement of macrophage
CD36-mediated phagocytosis of P. falciparum, anti-apop-
tosis agents, heparin, anti-convulsants and erythropoietin,
which are based on a different patho-physiological ratio-
nale. Only anti-convulsants, exchange blood transfusions,
osmotic diuretics and pentoxifylline have been shown to
be partially effective [10].
Statins, inhibitors of 3-hydroxy-3-methylglutaryl-Coen-
zyme A reductase (HMG-CoA reductase), a family of
lipid-lowering drugs, have recently been demonstrated to
have pleiotropic cholesterol-independent effects. They
reduce the “mevalonate pathway”, which involves the
synthesis of isoprenoids and the intracellular trafficking of
membrane-associated proteins such as G-proteins. GTP-
binding proteins have crucial roles in intracellular inflam-
matory signalling by acting as molecular on/off switches
for various protein kinases. Although many subfamilies
have been described, the farnesylated Ras subfamily and
the geranylgeranylated Rho, Rac andCdc42 subfamilies are
the most important in the context of sepsis because of
their essential role in intracellular inflammatory signalling
[11].
Among their pleoiotropic effects, statins are recog-
nized to have the following:
- Anti-inflammatory action; they reduce systemic
inflammation by lowering the pro-inflammatory ten-
dencies of macrophages and neutrophils by reducing
Th1 and promoting Th2 development [11-13]. The
activation of T-lymphocytes and the control of the
immune response mediated by major histocompatibil-
ity complex class II (MHC-II) and CD40/CD40L are
inhibited by statins on endothelial, monocyte and
macrophage cells [14-16]. Statins inhibit NK-cell cyto-
toxicity by interfering with LFA-1-mediated adhesion
[17];
- An improvement of endothelial function by modu-
lating nitric oxide synthase (NOS) activity, and con-
sequently, nitric oxide levels by reducing inducible
NOS expression and by maintaining or increasing
endothelial constitutive NOS production [18-20].
Statins also directly decrease the expression of
endothelial adhesion molecules, such as ICAM-1,
VCAM-1 and E-selectin [21,22]; moreover, they can
prevent P. falciparum cytoadherence and endothelial
damage [23];
- A beneficial effect on the outcome of infection and
attenuating sepsis [11,24,25];
- A neuroprotective effect in the setting of cerebral
ischemia [26].
Cerebral malaria shares common pathophysiological
features with sepsis, especially with regard to the pathol-
ogy of the endothelium [27].
Of the different statins, atorvastatin (AVA) showed an
in vitro anti-malarial activity even though the presence of
an HMG-CoA reductase homologue was not revealed by
BLASTX comparison of the P. falciparum genome
against other protozoal HMG-CoA reductase protein
sequences [28,29]. Nevertheless, AVA, used alone at 20
mg/kg of body weight, failed to prevent death from cere-
bral malaria or to affect the parasitaemia of infected mice
[30]. Moreover, AVA improved the in vitro activity of
MQ [31], quinine [32] or dihydroartemisinin [33] at the
plasma concentrations expected in clinical observations
in patients taking 80 mg of AVA daily (0.1 to 0.5 μM)
[34].
The different mechanisms of AVA as immunomodula-
tor, neuroprotector and potentialisator of anti-malarial
drugs call for in vivo evaluation. Animal models do not
exactly reproduce human malaria, but they nevertheless
exhibit some similarities to human CM, and the use of the
Plasmodium berghei ANKA rodent parasite model is gen-
erally accepted as one of the valid models for studying
experimental cerebral malaria (ECM) pathogenesis [4,35].
The aim of the present work was to test AVA efficacy in
a murine model on parasitaemia or death (ECM or severe
anaemia) and define schemes of drug use in prophylaxis,
alone or in combination. For prophylaxis strategy, meflo-
quine was chosen as anti-malarial drug. The effects on
ECM were determined through the evaluation of brain
histopathological changes and neuronal apoptosis. The
efficacy of AVA used alone in a therapeutic strategy was
evaluated to confirm previous studies.
Methods
Mice and ECM
A total of 211 female CBA/J mice, 6-7 weeks old and
weighing 18-22 g, from Charles River (France), were
used in five independent experiments: 128 for the survi-
val studies and 83 for organ sampling and histological
analysis. All animals were pathogen-free and were
housed under standard conditions, with unlimited access
to food and water. All experiments adhered to French
guidelines for animal research and were approved by the
ethical committee of the Institut de Recherche Biomédi-
cale des Armées-Antenne de Marseille (Number 2007-
02). All efforts were made to minimize animal suffering.
Mice were infected on day 0 (D0) with P. berghei
ANKA parasites by intraperitoneal (i.p.) inoculation with
107 pRBC from infected donor CBA/J mice, diluted in
normal saline.
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Experimental design for drug use
Mice were treated with AVA calcium salt dissolved in 1%
dimethyl sulfoxyde (vol/vol) in 0.9% NaCl at various
dosages: 2, 40 or 80 mg/kg of body weight; and/or MQ
dissolved in 1% methanol (vol/vol) in 0.9% NaCl at various
dosages: 0.5, 2 or 10 mg/kg of body weight. Control mice
(CT) were treated with NaCl (0.9%) only. Treatment was
injected in 0.4 ml by i.p. inoculation using different
schemes (Figure 1).
Curative treatment was AVA alone with i.p. injections
in four groups of eight mice from D2 to D7: control,
2 mg/kg AVA, 40 mg/kg AVA and 80 mg/kg AVA,
respectively (Figure 1, scheme 1).
Prophylaxis treatment was AVA and/or MQ with i.p.
injections in five groups of eight mice from D-3 to D2:
control, 40 mg/kg AVA, 80 mg/kg AVA, 2 mg/kg MQ
and 2 mg/kg MQ associated with 40 mg/kg AVA,
respectively (Figure 1, scheme 2).
Prophylaxis treatment was AVA from D-3 to D6 and/or
MQ D-3 and D3 with i.p. injections in six groups: control,
40 mg/kg AVA, 10 mg/kg MQ, 2 mg/kg MQ, 0.5 mg/kg
MQ and 2 mg/kg MQ associated with 40 mg/kg AVA,
respectively (Figure 1, scheme 3). Survival studies were ter-
minated by an animal’s death or by killing animals that
presented clear signs of CM.
Control, 40 mg/kg AVA, 2 mg/kg MQ and 2 mg/kg MQ
associated with 40 mg/kg AVA groups were assessed for
histological samples (Figure 1, scheme 4) according to
Figure 1, scheme 2, i.e., prophylaxis treatment with AVA
and/or MQ with i.p. injections from D-3 to D2. Blood,
brain, lung, and spleen samples were taken systematically
in each group on D0, D2, and D5; in pre-moribund mice
with ECM signs on D6-9 in the control group matched
with mice of other groups, on D14 matched with combi-
nation group and according to the results of Figure 1,
scheme 2 experiments.
Parasitaemia and clinical parameters
Parasitaemia was determined daily using Giemsa-stained
thin blood smears collected from the tailed vein, as the
number of infected red blood cells per 3,000 erythrocytes
if > 1% and per 10,000 erythrocytes if < 1%. The animals
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Figure 1 Experimental design.
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were under daily supervision for clinical signs, neurological
symptoms and weight.
ECM was diagnosed by clinical signs based on a simpli-
fied SHIRPA protocol [36] with at least two symptoms in
at least two of the three different groups:
1. Alteration of autonomous function (piloerection,
defecation, urination, respiration rate),
2. Alteration of muscle tone and strength (grip
strength, body tone, limb tone, abdominal tone),
3. Ataxia, paralysis (mono-, hemi-, para-, or tetraple-
gia), deviation of the head, convulsions and coma.
Organ sampling and histology
Organ sampling was performed according to Figure 1,
scheme 4 systematically or in pre-moribund mice with
ECM signs. Brains were carefully removed, and cerebral
hemispheres were separated: one was frozen at -20°C in
RNALater (Qiagen, Germany) for further RNA analysis,
and the other one was fixed by immersion in 4% parafor-
maldehyde with alcohol and acetic acid (AFA) for 48 h.
Hemispheres were cut in five coronal sections (rhinence-
phalon, striatum, hippocampus, posterior thalamus nuclei
and cerebellum) [36], embedded in paraffin and serial
sections (three at 5 μm), two of which were stained routi-
nely with haematoxylin-eosin-saffron and one that was
used for in situ DNA fragmentation detection. Sections
were examined by light microscopy, and pictures were
taken using a digital camera (Digital Camera DXM1200,
Nikon).
In situ detection of DNA fragmentation
Terminal deoxynucleotidyl transferase (TdT)-mediated
deoxyuridine triphosphate (dUTP)-digoxigenin nick end
labelling (TUNEL) staining was performed according to
the manufacturers’ protocol, using the TdT-FragEL DNA
Fragmentation Detection Kit (Oncogene Research Pro-
ducts, Cambridge, UK). DAB was used as a chromogen,
and the sections were counterstained with methyl green.
Cellular counting was carried out in a randomized manner
by a single investigator. TUNEL + cells were counted in
the five coronal sections of one hemisphere.
Statistical analysis
All statistical analyses were realised with R software (ver-
sion 2.4.1). Survival analyses were performed by the
Kaplan-Meier log rank test. Box plot graphs outlined the
25th and 75th percentiles and the median, with bars repre-
senting the minimum and maximum. Box plot graphs
were realised with GraphPad Prism 5 software. Parasitae-
mia were compared by Fisher’s exact test. Comparison of
medians between multiple groups were analysed by the
Kruskal-Wallis test. Comparison of medians between two
groups were analysed by the Mann-Whitney test. A differ-
ence was considered significant for P-values < 0.05.
Results
AVA effects on mortality and parasitaemia in ECM
Experimental scheme 1, Figure 1
In the curative treatment with injection of AVA alone
from D2 to D7, there was no significant difference (p =
0.72) in survival between untreated mice and mice treated
with a high dose (80 mg/kg), middle dose (40 mg/kg) or
low dose (2 mg/kg); nor was there any significant effect on
the evolution of parasitaemia.
Experimental scheme 2, Figure 1
In this first prophylaxis experiment, 80% of the mice of the
control group (CT) and the AVA treated group died with
ECM specific signs between D6 and D9 with less than 30%
parasitaemia (19.5 to 27%). All of the mice of the two
groups died before D12. There was no significant differ-
ence between these two groups (p = 0.403). Fifty percent
of the mice treated with 2 mg/kg of MQ died, some of
them exhibiting signs of ECM (2/4), between D11 and
D14, and all died before D18 with less than 30% parasitae-
mia. Survival was significantly different between CT- and
MQ-treated mice (p < 0.001). Mice treated with the com-
bination of AVA and MQ died between D19 and D32
without signs of ECM. Parasitaemia in this group was
greater than 60%. Survival was significantly prolonged in
mice treated with the combination (p < 0.001) compared
to the CT group and to the group treated with MQ alone
(p < 0.001) (Figure 2).
Experimental scheme 3, Figure 1
To confirm the effects of the AVA and MQ combination,
another treatment scheme was evaluated with a prophy-
lactic MQ administration identical to once-weekly human
prophylaxis. As the recommended prophylactic dose of
MQ is 3 to 5 mg/kg, three different doses were tested:
0.5 mg/kg, 2 mg/kg and 10 mg/kg. A combination AVA
and MQ dose was 40 mg/kg AVA and 2 mg/kg MQ.
There was no statistical difference in parasitaemia evolu-
tion between the CT group and the group treated with
AVA alone or mice treated with 0.5 mg/kg or 2 mg/kg
MQ. The group treated with 10 mg/kg MQ showed a
decrease in parasitaemia from 8.1% on D5 to 0% on D7
until D12 and then a rapid increase to greater than 40%
on D18, with the death of all mice between D18 and D20.
In the group treated with the combination of AVA and
MQ, parasitaemia increased to 60% on D18, and all mice
died between D18 and D22. There was no significant dif-
ference in survival between untreated mice and mice trea-
ted with 2 mg/kg MQ (p = 0.968). Survival was statistically
higher in the mice treated with the combination of AVA
and 2 mg/kg MQ compared to the two previous groups,
the CT group (p < 0.001) and the 2 mg/kg MQ group (p =
0.001) (Figure 3).
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Histological analysis
Histological analysis was done on all brains from D0 to
D14, and all samples were taken during the Figure 1,
scheme 4 experiment. Only CT group mice presented CM
signs at D5 (4/5), but all mice in the CT and AVA groups
exhibited CM-specific signs at D8; no mouse developed
CM signs in the other groups. Only one (1/4) developed
CM symptoms at D14 in the MQ group. Qualitative histo-
pathological findings included parenchymal haemorrhages
with petechial (Figure 4B), perivascular (Figure 4C) or
laminated with occasional haemozoin pigment (Figure
4D), microhaemorrhagic areas, frequently in the cerebel-
lum (Figure 4F), subarachnoid haemorrhages (Figure 4E),
perivascular oedema with few extravasated mononuclear
cells and vascular plugging by pigment-containing mono-
cytes/macrophages (Figure 4G). These mononuclear cells
adhered to endothelial cells, and sometimes small and
activated lymphocytes were observed. Vascular plugging
and adherence of monocytes to endothelial cells were
intense in all animals with CM at D8.
No histological lesions were detected in non-infected
mice at D0. Increasing numbers of ring haemorrhages
were observed at D5 with a significant difference
between the CT group and the MQ group (p = 0.01);
clinical signs of CM appeared at D5 in the control
group. Focal haemorrhages continued to rise at D8 in
CT and AVA group, whereas they stayed similar in the
MQ and AVA + MQ groups (p = 0.02 and p = 0.01,
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Figure 2 Survival and parasitaemia level in CBA/J mice infected with PbA and treated with AVA, MQ or AVA + MQ according to
Figure 1, scheme 2.
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respectively). A significant difference was observed at
D14 with the increase of haemorrhages in the MQ
group (p = 0.03) (Figure 4A).
Apoptotic neurons analysis
The analysis of apoptosis of neurones was performed on
the same samples used for histology analysis. TUNEL +
cells showed a tendency to cluster but were sometimes
isolated. The number of apoptotic neurons appeared to
be increased at D5, with a significant difference between
the CT and MQ groups (p = 0.032). At D8, TUNEL +
cells were less numerous but were significantly lower in
the AVA + MQ group, with a median around 25 apop-
totic cells per slide, compared to the CT group, which
had a median around 270 apoptotic cells per slide (p =
0.032). No difference was observed between the two
groups remaining at D14 (Figure 4H-J).
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Figure 3 Survival and parasitaemia level in CBA/J mice infected with PbA and treated with AVA, MQ or AVA + MQ according to
Figure 1, scheme 3.
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Discussion
These results confirm that in the experimental cerebral
malaria model, AVA (used alone) in a therapeutic i.p.
treatment shows no effect on the incidence of cerebral
malaria or parasitaemia, as previously described [37].
Several statins, such as simvastatin, pravastatin and flu-
vastatin, used alone are ineffective in cerebral malaria
and have no effect on the incidence of parasitaemia dur-
ing experimental malaria [30,37,38]. In the prophylactic
scheme, AVA associated with MQ versus MQ alone
leads to a significant delay in mouse death and has an
effect on the onset of CM symptoms and on the level of
parasitaemia. These experimental conditions did not
prevent death, but it appears to be that mice of the
combination group did not die of cerebral malaria, as
the mice in the three other groups did. Instead, they
died of anaemia, with parasitaemia > 60%. Treatment in
the MQ group delayed the evolution of parasites, but at
the end of the therapeutic effect, parasitaemia increased
and CM symptoms appeared.
Experimental models cannot reproduce all the features
of human diseases. Differences from the human disease
include that leucocytes rather than pRBC are the main
cells sequestered in brain vessels, that there are no
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Figure 4 Histological and TUNEL analysis of mouse brains, sampled according to Figure 1, scheme 4. (A) Number of perivascular and
interstitial haemorrhages in two 5 μm serial sections per mouse, in each group from Figure 1, scheme 4. (D0CT = control group at day 0;
D0AVA = group with atorvastatin at day 0; D5CT = control group at day 5; D5AVA = group with atorvastatin at day 5; D5MQ = group with
mefloquine at day 5; D5MAAVA = group with MQ + AVA at day 5; D8CT = control group at day 8; D8AVA = group with atorvastatin at day 8;
D8MQ = group with mefloquine at day 8; D8MQAVA = group with MQ + AVA at day 8; D14MQ = group with mefloquine at day 14;
D14MQAVA = group with MQ + AVA at day 14). Significant differences between D5CT and D5MQ, D8CT and D8MQ, D8CT and D8MQAVA, and
D14MQ and D14MQAVA. (B) HES staining. Petechial haemorrhage 400×. (C) Perivascular haemorrhage 1000×. (D) Interstitial haemorrhage area
with haemozoin pigment 400×. (E) Subarachnoid haemorrhage. (F) Cerebellum perivascular and interstitial haemorrhage 400×. (G) Vascular
plugging by monocytes/macrophages (sometimes pigment-containing) with perivascular oedema and few extravasated mononuclear cells
1,000×. (H) Number of apoptotic nuclei in one section per mouse from each group of Figure 1, scheme 4; TUNEL + staining (brown colour with
DAB). (I) TUNEL + neurons revealing apoptotic nuclei; 1000×. (J) Focal cerebellar area stained with TUNEL + and showing an interstitial
haemorrhage (arrow); 200×. (D0CT = control group at day 0; D0AVA = group with atorvastatin at day 0; D2CT = control group at day 2;
D2AVA = group with atorvastatin at day 2; D2MQ = group with mefloquine at day 2; D2MQAVA = group with MQ + AVA at day 2; D5CT =
control group at day 5; D5AVA = group with atorvastatin at day 5; D5MA = group with mefloquine at day 5; D5MQAVA = group with MQ +
AVA at day 5; D8CT = control group at day 8; D8AVA = group with atorvastatin at day 8; D8MQ = group with mefloquine at day 8; D8MQAVA =
group with MQ + AVA at day 8; D14MQ = group with mefloquine at day 14; D14MQAVA = group with MQ + AVA at day 14).
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knobs on pRBC and mice do not develop a high fever
[4]. However, the model based on CBA/J mice infected
by PbA exhibits primary features also seen in human
CM: a clinical picture including coma, seizures and neu-
rological impairment, strong histopathological similari-
ties with impairment of the blood brain barrier,
petechial bleedings and systemic and local immune
responses involving TNF, INF-g and IL-1b as pro-
inflammatory cytokines [5,35,37,39]. In the present
study, as is common, death occurs in six-10 days and
involves 80 to 90% of the mice. Different host-parasite
factors such genetic background, age, amount of inocu-
lum, course of parasitaemia and clonal variations of the
parasite may also interfere with the incidence of CM
and may explain the different levels of parasitaemia in
our experiments [39].
The major histopathological findings in the brain were
petechial haemorrhages predominantly localized in the
deep white matter and cerebellum, perivascular oedema
and vascular plugging by leucocytes; these changes are
similar to those that have been described previously
[36,40,41]. However, murine CM does not present reli-
able histopathological indicators: mice without CM signs
may have brain lesions and haemorrhagic areas affecting
0.19% of total cerebral area in mice with clinical signs
versus 0.04% in mice without signs [40]; the present data
demonstrate a significant increase in brain haemorrhages
in mice with CM symptoms. Some studies reported a
higher frequency of haemorrhagic foci in the brains of
mice showing signs of cerebral involvement when com-
pared with infected animals without clinical manifesta-
tion [36,40,41].
Wiese et al. [42] found apoptosis of neurons as well as
apoptosis of endothelial cells in the brains of mice with
ECM in terminally ill animals, with clear clinical signs of
cerebral involvement on days 10-13 after inoculation.
Using the same techniques as Wiese, an earlier apoptotic
effect was found with an increase in apoptotic neuron
nuclei at D5. This may be linked with the high level of
parasitaemia in this experiment (at D5: CT 20.8%, AVA
18.6%, MQ 5%, AVA + MQ 9.6%) compared to the para-
sitaemia level found in Weise’s study, at 7.5% for mice
with severe symptoms of CM (D10 to D13). The anti-
apoptotic effect of AVA in the AVA + MQ combination
groups could not be demonstrated here, despite protec-
tion against cerebral malaria by the combination. Further
studies are needed to confirm the apoptosis effect in
AVA treatment.
Conclusions
Association AVA + MQ is effective in a prophylactic
scheme and can potentiate the action of MQ. Immunodu-
lation by AVA is associated with protection against CM.
Further immunological study of AVA and AVA + MQ in
an ECM model is required and should involve microarray
analyses on the brain and cytokine assays. However, effects
of AVA + MQ were only evaluated in a prophylactic strat-
egy and not in a treatment strategy. This limits the poten-
tial use of AVA. Further studies on the therapeutic
treatment scheme are needed to validate AVA as a new
partner drug. Resistance to artemisinin-based combination
therapy is emerging in southern Cambodia and Thailand,
especially the mefloquine-artesunate combination [43]. All
these observations support calls for clinical trials of AVA
as an anti-malarial therapy.
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